Prostate cancer therapy: Going forwards by going backwards

The Lancet Oncology

Volumn 14, Issue 2, 2013, Pages 104-105

  Sweeney, Christopher ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CYPROTERONE ACETATE; CYTOTOXIC AGENT; DOCETAXEL; HORMONE; RADIOPHARMACEUTICAL AGENT;

CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RESISTANCE; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; COMORBIDITY; DRUG EFFICACY; DRUG POTENCY; DRUG SENSITIVITY; FOLLOW UP; HUMAN; LETTER; OVERALL SURVIVAL; PATIENT CARE; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RETREATMENT; SAMPLE SIZE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 84873091555     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70591-0     Document Type: Letter

References (10)

1. Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013, published online Jan 8. http://dx.doi.org/10.1016/S1470-2045(12)70560-0.
2. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
3. James ND, Sydes MR, Mason MD, et al. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol 2012, 13:549-558.
4. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995, 346:265-269. Prostate Cancer Trialists' Collaborative Group.
5. Millikan RE, Wen S, Pagliaro LC, et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 2008, 26:5936-5942.
6. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
7. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364:1995-2005.
8. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012, 367:1187-1197.
9. Parker C, Heinrich D, O'Sullivan JM, et al. Overall survival benefit of radium-223 chloride (alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA). European Cancer Organisation and European Society for Medical Oncology Annual Meeting; Stockholm; Sept 23-27, 2011.
10. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154.